EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies

Peter R McIlroy, Le Thanh Mai Pham, Thomas Sheffield, Maxwell A Stefan, Christine E Thatcher, James Jaryenneh, Jennifer L Schwedler, Anupama Sinha, Christopher A Sumner, Iris K A Jones, Stephen Won, Ryan C Bruneau und 6 weitere

PLOS Pathogens · 23.01.2025 · 21 (1) · e1012903

DOI: 10.1371/journal.ppat.1012903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 23.01.2025. Verfasst von Peter R McIlroy und 17 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology and Bioengineering, Sandia National Laboratories, Livermore, California, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, Machine Learning, Antibodies, Neutralizing, Single-Domain Antibodies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Energy (DOE), Sandia National Laboratories, Honeywell.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to persist, demonstrating the risks posed by emerging infectious diseases to national security, public health, and the economy. Development of new vaccines and antibodies for emerging viral threats requires substantial resources and time, and traditional development platforms for vaccines and antibodies are often too slow to combat continuously evolving immunological escape variants, reducing their efficacy over time. Previously, we designed a next-generation synthetic humanized nanobody (Nb) phage display library and demonstrated that this library could be used to rapidly identify highly specific and potent neutralizing heavy chain-only antibodies (HCAbs) with prophylactic and therapeutic efficacy in vivo against the original SARS-CoV-2. In this study, we used a combination of high throughput screening and machine learning (ML) models to identify HCAbs with potent efficacy against SARS-CoV-2 viral variants of interest (VOIs) and concern (VOCs). To start, we screened our highly diverse Nb phage display library against several pre-Omicron VOI and VOC receptor binding domains (RBDs) to identify panels of cross-reactive HCAbs. Using HCAb affinity for SARS-CoV-2 VOI and VOCs (pre-Omicron variants) and model features from other published data, we were able to develop a ML model that successfully identified HCAbs with efficacy against Omicron variants, independent of our experimental biopanning workflow. This biopanning informed ML approach reduced the experimental screening burden by 78% to 90% for the Omicron BA.5 and Omicron BA.1 variants, respectively. The combined approach can be applied to other emerging viruses with pandemic potential to rapidly identify effective therapeutic antibodies against emerging variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Machine LearningAntibodies, NeutralizingSingle-Domain AntibodiesCOVID-19Antibodies, ViralImmunoglobulin Heavy ChainsHumansPeptide LibrarySpike Glycoprotein, CoronavirusAnimalsHigh-Throughput Screening Assays

Substanzen

Antibodies, NeutralizingSingle-Domain AntibodiesAntibodies, ViralImmunoglobulin Heavy ChainsPeptide LibrarySpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Biotechnology and Bioengineering, Sandia National Laboratories, Livermore, California, United States of America.
  • Bioresource and Environmental Security, Sandia National Laboratories, Livermore, California, United States of America.
  • Biosecurity and Bioassurance, Sandia National Laboratories, Livermore, California, United States of America.
  • Systems Biology, Sandia National Laboratories, Livermore, California, United States of America.
  • Biosciences and Biotechnology Division, Lawrence Livermore National Laboratories, Livermore, California, United States of America.
  • Department of Molecular Microbiology, School of Medicine, Washington University, St. Louis, M issouri, United States of America.

ORCID-Profile: Brooke Harmon

Förderung

  • Department of Energy (DOE)
  • Sandia National Laboratories
  • Honeywell
  • Office of Science

Zitieren

APA

McIlroy, P. R., Pham, L. T. M., Sheffield, T., Stefan, M. A., Thatcher, C. E., Jaryenneh, J., Schwedler, J. L., Sinha, A., Sumner, C. A., Jones, I. K. A., Won, S., Bruneau, R. C., Weilhammer, D. R., Liu, Z., Whelan, S., Negrete, O. A., Sale, K. L., & Harmon, B. (2025). Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies. PLOS Pathogens, 21(1), e1012903. https://doi.org/10.1371/journal.ppat.1012903

Vancouver

McIlroy PR, Pham LTM, Sheffield T, Stefan MA, Thatcher CE, Jaryenneh J, et al. Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies. PLOS Pathogens. 2025;21(1):e1012903. doi:10.1371/journal.ppat.1012903

BibTeX
@article{McIlroy2025,
  author = {McIlroy, Peter R and Pham, Le Thanh Mai and Sheffield, Thomas and Stefan, Maxwell A and Thatcher, Christine E and Jaryenneh, James and Schwedler, Jennifer L and Sinha, Anupama and Sumner, Christopher A and Jones, Iris K A and Won, Stephen and Bruneau, Ryan C and Weilhammer, Dina R and Liu, Zhuoming and Whelan, Sean and Negrete, Oscar A and Sale, Kenneth L and Harmon, Brooke},
  title = {Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies},
  journal = {PLOS Pathogens},
  year = {2025},
  volume = {21},
  number = {1},
  pages = {e1012903},
  doi = {10.1371/journal.ppat.1012903}
}
Kostenlos starten →